Solid Biosciences Inc. shares plunged in the extended session Wednesday, following a halt, after the muscular dystrophy treatment maker announced a clinical trial had been put on hold. Solid Biosciences shares sank 50%, after closing down 0.5% at $26.31 Wednesday. The company, which focuses on treatments for Duchenne muscular dystrophy, said a study of its treatment SGT-001 was placed on clinical hold by the Food and Drug Administration following an unexpected adverse reaction in one of the patients on the treatment. Following the treatment, the patient was hospitalized for a reduced blood platelet and red blood cell count, and is now without symptoms, Solid said. In late January, gene therapy researcher James Wilson quit Solid Biosciences’s advisory board and the company revealed the FDA had placed a “partial clinical hold” on the SGT-001 study just before Solid priced its initial public offering.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News